2024年3月18-21日，DCAT Week会议（美国药品和化学品联合交易协会年会）在美国纽约顺利举办，诺泰生物董事长童梓权、副董事长金富强、营销中心副总经理李小华，带领BD团队出席了本次盛会。DCAT Week是医药研发和生产以及相关行业领域企业的首要业务开发盛会，汇聚了众多全球知名医药企业和相关领域专业人士。DCAT是一个非营利性的全球商业发展协会，其独特的会员模式整合了创新药和仿制药制造商以及原料、开发和制造服务以及相关技术的供应商。
会议期间，诺泰生物与全球药企领袖一起探索行业发展趋势与技术发展方向，多肽药物的临床应用范围不断扩大、重磅新品陆续上市，诺泰生物以多肽特色原料药为优势业务，以创新驱动发展，围绕全球的重大临床需求与技术进步，大力推进重磅仿制药的产品布局，利用学科交叉的研发能力，深耕多肽和小核酸CDMO领域，服务全球客户。
此次BD团队亮相美国，全面展示BD的专业化与国际化，多肽行业领军人物姜建军博士（诺泰生物副总经理），李唐擎博士（诺泰生物副总经理），新加入的BD总监乔桢博士和Connor Jack Thomson博士等参与客户洽谈。
乔桢博士
乔桢博士在美国德雷塞尔大学获得了博士学位，并随后在布朗大学从事博士后研究。他的研究兴趣包括基因治疗、生物医学应用的新材料，以及用于小/大分子发现和生物信息学的计算化学。在生物技术和生物制药研发方面，乔博士具有扎实的背景和丰富的经验。
Connor Jack Thomson博士
Connor Jack Thomson博士毕业于牛津大学，有机化学专业，博士学位，曾在英国高科技公司CRO Cortex Organics担任研究总监，拥有良好的化学专业和药物开发功底。
童梓权表示，他们作为诺泰生物BD团队的新鲜血液，将加速诺泰生物的BD能力从Random到Mapping的转变，对进一步布局海外市场，实现全球业务战略，具有重要意义。
From March 18th to 21st, 2024, the DCAT Week, the annual meeting of the United States Association for Drug and Chemical Transactions, was successfully convened in New York, USA. Leading the BD team, Tong Ziquan, Chairman of SINOPEP, along with Jin Fuqiang, Vice Chairman, and Li Xiaohua, Deputy General Manager of Marketing Center, attended this significant event. DCAT Week stands as the premier platform for business development within the pharmaceutical R D, manufacturing, and related sectors, gathering esteemed professionals and leading companies from around the globe. DCAT, a non-profit global business development association, uniquely integrates manufacturers of innovative and generic drugs with suppliers of raw materials, development and manufacturing services, and associated technologies.
Throughout the conference, SINOPEP collaborated with global pharmaceutical leaders to explore industry trends and technological advancements. The clinical application scope of peptide drugs continued to broaden, accompanied by the successive launch of new groundbreaking products. SINOPEP has strategically positioned peptide specialty APIs as its primary focus, prioritizing innovation-driven development. It has actively promoted the global distribution of blockbuster generic drugs, aligning with major clinical demands and technological advancements worldwide. Leveraging interdisciplinary research and development capabilities, SINOPEP is dedicated to enhancing its offerings in the fields of polypeptides and small nucleic acid CDMO, catering to the needs of global clientele.
The presence of the BD team at the conference underscored the specialization and internationalization of SINOPEP''s BD efforts. Notably, industry leader Dr. Jiang Jianjun, Deputy General Manager of SINOPEP, Dr. Li Tangqing, Deputy General Manager of SINOPEP, alongside Dr. Qiao Zhen and Dr. Connor Jack Thomson, new BD directors who joined SINOPEP, actively engaged in customer negotiations, reaffirming SINOPEP''s commitment to excellence in the peptide industry.
Dr. Qiao Zhen
Dr. Qiao Zhen obtained his doctoral degree from Drexel University and subsequently pursued postdoctoral research at Brown University in the United States. His research interests encompass gene therapy, novel materials for biomedical applications, and computational chemistry for small/large molecule discovery and bioinformatics. With a robust background in biotechnology and biopharmaceutical research and development, Dr. Qiao brings extensive expertise to his field.
Dr. Connor Jack Thomson
Dr. Connor graduated from the University of Oxford with a PhD in Organic Chemistry. He previously served as the Research Director at CRO Cortex Organizations, a high-tech company in the UK. He has a strong background in chemistry and drug development.
Mr Tong Ziquan stated that as fresh blood to SINOPEP''s BD team, they will accelerate the transformation of SINOPEP''s BD capabilities from "Random" to "Mapping", which is of great significance for further expanding overseas markets and achieving global business strategies.